Thrombotic thrombocytopenic purpura (TTP) is a medical emergency that requires immediate hospital treatment. Without it, the mortality rate exceeds 90%. With modern treatment, that number drops significantly, though it still ranges between 10% and 20% depending on the severity and how quickly care begins. The core of treatment involves filtering the blood through a process called plasma exchange, suppressing the immune system, and in many cases using a newer drug that stops dangerous blood clots from forming.
What Happens in TTP and Why It’s Urgent
TTP occurs when the body lacks a critical enzyme (called ADAMTS13) that normally trims a sticky blood-clotting protein down to size. Without enough of this enzyme, oversized clotting proteins accumulate in the bloodstream and cause platelets to clump together into tiny clots throughout the body’s small blood vessels. These clots can damage the brain, kidneys, heart, and other organs within hours.
In the immune form of TTP, which is the most common type in adults, the body’s own antibodies attack and disable the enzyme. A blood test showing enzyme activity below 10% confirms the diagnosis and distinguishes TTP from other conditions that look similar. Because waiting for that lab result can take days, doctors typically start treatment right away based on clinical suspicion: a combination of low platelets, signs of red blood cell destruction, and organ involvement.
Plasma Exchange: The Foundation of Treatment
Plasma exchange is the single most important intervention for TTP. It works in two ways at once: it removes the harmful antibodies and oversized clotting proteins from your blood, and it replaces them with donor plasma that contains functional enzyme. Before plasma exchange became standard practice, TTP was almost universally fatal.
During the procedure, blood is drawn from a large IV line, run through a machine that separates and discards your plasma, and returned to your body with fresh donor plasma. Each session exchanges roughly one full plasma volume, which works out to about 40 mL per kilogram of body weight. For a 70-kilogram person, that’s close to 3 liters of plasma swapped out in a single session.
Sessions happen once daily and continue until platelet counts stabilize above 150,000 per microliter for at least 48 hours. For most people, this takes somewhere between one and three weeks, though some cases resolve faster and others take longer. In severe or slow-responding cases, doctors may increase to twice-daily sessions or exchange larger volumes.
Immune Suppression With Steroids
Because the immune form of TTP is driven by antibodies attacking the enzyme, steroids are started alongside plasma exchange to tamp down the immune response. High-dose steroids reduce antibody production and help control the underlying autoimmune attack. They’re typically given intravenously during the acute phase and then transitioned to oral doses that are gradually tapered as the condition improves.
Steroids alone aren’t enough to treat TTP, but they’re an essential complement to plasma exchange. They help shorten the duration of the acute episode and reduce the total number of plasma exchange sessions needed.
Caplacizumab: Stopping Clots Faster
Caplacizumab is a newer targeted drug that blocks the oversized clotting protein from grabbing onto platelets. This directly prevents the tiny clots that cause organ damage in TTP. In a landmark trial published in the New England Journal of Medicine, patients who received caplacizumab alongside plasma exchange and steroids had faster platelet recovery and fewer clot-related complications than those on placebo.
The drug is given as a one-time intravenous dose before the first plasma exchange session, then as a daily injection under the skin throughout the course of plasma exchange and for 30 days afterward. If your enzyme levels remain severely low after those 30 days, treatment can be extended for up to an additional 28 days while your immune suppression is adjusted. The main side effect to be aware of is an increased risk of bleeding, since the drug works by interfering with part of the clotting process.
Rituximab for Stubborn or Relapsing Cases
Rituximab targets and depletes a specific type of immune cell responsible for producing the harmful antibodies. It’s increasingly used early in treatment, especially for patients who aren’t responding quickly to plasma exchange and steroids, or for those with very low enzyme activity suggesting a strong autoimmune attack.
The standard approach is a weekly infusion for four consecutive weeks, given right after a plasma exchange session so the drug isn’t immediately washed out. Rituximab takes a few weeks to reach full effect, so it doesn’t replace the need for plasma exchange in the short term. Its real value is in achieving deeper, longer-lasting immune suppression that reduces the risk of relapse. Some patients also receive it preventively if monitoring shows their enzyme levels dropping again months or years later.
Why Platelet Transfusions Are Avoided
This is one of the most counterintuitive aspects of TTP treatment. Despite dangerously low platelet counts, giving platelet transfusions is generally considered harmful. The logic is straightforward once you understand the disease: TTP causes platelets to clump into clots. Adding more platelets can be like adding fuel to a fire. Research has found that platelet transfusions in TTP patients are associated with six times higher odds of arterial blood clots and twice the odds of heart attack, even after accounting for how sick the patient was. Autopsies of TTP patients have confirmed that platelets are the main component of the damaging clots.
Platelet transfusions are reserved only for life-threatening bleeding or unavoidable surgical procedures. In fact, once platelet counts begin recovering, some treatment protocols actually add a low-dose blood thinner to prevent clots from forming during the recovery phase.
When Standard Treatment Doesn’t Work
A small percentage of TTP cases are refractory, meaning they don’t respond to the combination of plasma exchange, steroids, and rituximab. For these patients, options include stronger immune-suppressing drugs like cyclophosphamide or cyclosporine, or in rare cases, surgical removal of the spleen. The evidence for these approaches comes mainly from small case series rather than large trials, but they remain important lifelines for patients who’ve exhausted first-line options.
Long-Term Monitoring After Recovery
Surviving the acute episode is only part of the picture. TTP relapses are a real and ongoing risk, and the strongest predictor of relapse is a drop in enzyme activity levels. Most patients need blood tests to check their enzyme levels every three to six months for as long as levels remain normal. If enzyme activity never fully recovers after the initial episode, monitoring needs to be more frequent, typically every three months or sooner.
Late relapses can occur years after the initial episode, which is why lifelong monitoring is recommended for all TTP patients. A drop in enzyme activity, even without symptoms, is a signal that preemptive treatment with rituximab or other immune suppression may be needed to prevent a full-blown relapse. Many patients find it reassuring to know that catching these early warning signs through routine bloodwork can prevent another emergency hospitalization.